Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16870435rdf:typepubmed:Citationlld:pubmed
pubmed-article:16870435lifeskim:mentionsumls-concept:C0015520lld:lifeskim
pubmed-article:16870435lifeskim:mentionsumls-concept:C1521827lld:lifeskim
pubmed-article:16870435lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:16870435lifeskim:mentionsumls-concept:C1553032lld:lifeskim
pubmed-article:16870435pubmed:issue19lld:pubmed
pubmed-article:16870435pubmed:dateCreated2006-8-25lld:pubmed
pubmed-article:16870435pubmed:abstractTextPreviously, potent factor Xa inhibitors were described based on the 1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one bicyclic core and a 4-methoxyphenyl P1 moiety. This manuscript describes 1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one and related bicyclic cores with the 3-aminobenzisoxazole P1 moiety. Many of these compounds are potent, selective, and efficacious inhibitors of coagulation factor Xa.lld:pubmed
pubmed-article:16870435pubmed:languageenglld:pubmed
pubmed-article:16870435pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16870435pubmed:citationSubsetIMlld:pubmed
pubmed-article:16870435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16870435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16870435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16870435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16870435pubmed:statusMEDLINElld:pubmed
pubmed-article:16870435pubmed:monthOctlld:pubmed
pubmed-article:16870435pubmed:issn0960-894Xlld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:WexlerRuth...lld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:LamPatrick...lld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:WongPancras...lld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:KnabbRobert...lld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:JonaJananJlld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:RossiKaren...lld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:LuettgenJosep...lld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:FevigJohn MJMlld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:BaiStephen...lld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:LiYun-LongYLlld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:CacciolaJosep...lld:pubmed
pubmed-article:16870435pubmed:authorpubmed-author:BuriakJosephJ...lld:pubmed
pubmed-article:16870435pubmed:issnTypePrintlld:pubmed
pubmed-article:16870435pubmed:day1lld:pubmed
pubmed-article:16870435pubmed:volume16lld:pubmed
pubmed-article:16870435pubmed:ownerNLMlld:pubmed
pubmed-article:16870435pubmed:authorsCompleteYlld:pubmed
pubmed-article:16870435pubmed:pagination5176-82lld:pubmed
pubmed-article:16870435pubmed:meshHeadingpubmed-meshheading:16870435...lld:pubmed
pubmed-article:16870435pubmed:meshHeadingpubmed-meshheading:16870435...lld:pubmed
pubmed-article:16870435pubmed:meshHeadingpubmed-meshheading:16870435...lld:pubmed
pubmed-article:16870435pubmed:meshHeadingpubmed-meshheading:16870435...lld:pubmed
pubmed-article:16870435pubmed:meshHeadingpubmed-meshheading:16870435...lld:pubmed
pubmed-article:16870435pubmed:meshHeadingpubmed-meshheading:16870435...lld:pubmed
pubmed-article:16870435pubmed:meshHeadingpubmed-meshheading:16870435...lld:pubmed
pubmed-article:16870435pubmed:meshHeadingpubmed-meshheading:16870435...lld:pubmed
pubmed-article:16870435pubmed:year2006lld:pubmed
pubmed-article:16870435pubmed:articleTitlePreparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa.lld:pubmed
pubmed-article:16870435pubmed:affiliationBristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA.lld:pubmed
pubmed-article:16870435pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:16870435lld:chembl